Gregory Hare, MD, Medical Director
Dr. Gregory Hare
Gregory Hare, MD
Dr. Gregory Hare joined Roswell Park Cancer Institute (RPCI) in 2000, as a fellow in the Department of Radiation Medicine.
Following completion of his training, Dr. Hare joined the faculty of RPCI in 2004 as an Assistant Professor in Radiation Medicine.
Since then, he served as the on-site Medical Director of Radiation Medicine at both Buffalo Medical Group (BMG) in Williamsville, New York and more recently at Cayuga Medical Center (CMC) in Ithaca, New York.
Both organizations are premier affiliate sites of Roswell Park Cancer Institute
While serving as the on-site Medical Director for both BMG and CMC, Dr. Hare was instrumental in initiating new technologies to enhance radiation therapy delivery and to minimize side effects that can be associated with radiation treatment.
also facilitated the implementation of Roswell Park's first use of the video-teleconferencing technology.
This technology allows patient cases to be peer-reviewed, including review of pathology slides and radiation treatment plans, by the team of specialists at Roswell Park, prior to patients starting their radiation treatment.
This process ensures that patients are receiving the same radiation treatment plan that would be offered at Roswell Park.
Dr. Hare earned his medical degree from Loma Linda University in Southern California in 1997, followed by additional training in internal medicine at New York Medical College.
He is Board Certified in both Internal Medicine and Radiation Oncology.
areas of interest include cancers of the lung, head and neck, prostate, gastrointestinal system and breast.
He has authored a number of peer reviewed articles and abstracts in the areas of head and neck cancer, lung and breast cancers and is a member of many professional organizations.
Dr. Hare is excited about the role of Medical Director of the Mildred Milliman Radiation Medicine Center of Olean General Hospital.
plans for the near future include providing patients access to national clinical trials in radiation oncology and video-teleconferencing interface to facilitate peer review of all patient treatment plans prior to patients initiating treatment.